Ritratto di Vincenzo.Vullo@uniroma1.it

Previo appuntamento concordato via email

PROF. VINCENZO VULLO
CURRICULUM VITAE

http://www.farmaciamedicina.uniroma1.it/files/CV/CV_VULLO_VINCENZO_IT.pdf > Versione Italiana
http://www.farmaciamedicina.uniroma1.it/files/CV/CV_VULLO_VINCENZO_EN.pdf > English Version

INFORMAZIONI PERSONALI

Nome Vincenzo Vullo

Indirizzo professionale Dipartimento di Sanità Pubblica e Malattie Infettive Sapienza Università di Roma - Viale del Policlinico 155 - 00161 Roma
Telefono 0649970313
Fax 0649972625
E-mail vincenzo.vullo@uniroma1.it
Nazionalità Italiana
Codice Fiscale = VLLVCN49M20H501T

Data di nascita 20/08/1949

ESPERIENZE LAVORATIVE

Date (da a) Dal 1994 a tutt oggi
Nome e indirizzo del datore di lavoro Dipartimento di Sanità Pubblica e Malattie Infettive Sapienza Università di Roma
Tipo di azienda o settore Sapienza Università di Roma
Tipo di impiego Professore Ordinario di Malattie Infettive
Principali mansioni e responsabilità Preside Facoltà d Farmacia e Medicina Sapienza - Università di Roma
Direttore del DAI di Malattie Infettive e Tropicali - Azienda Policlinico Umberto I.
Direttore UOC di Malattie Infettive A - Azienda Policlinico Umberto I.
Titolare dei seguenti insegnamenti: Malattie Infettive nel Corso Integrato di Patologia Integrata V (V anno I semestre) del Corso di Laurea A in Medicina e Chirurgia; Malattie Infettive nel Corso Integrato di Medicina Clinica e Farmacologia (II anno I semestre) del Corso di Laurea B in Infermieristica; Farma¬cologia e Terapia delle Malattie Infettive al IV anno della Scuola di Spe¬cializzazione in Malattie Infettive.
Coordinatore del corso integrato di Pato¬logia Integrata V e del I semestre del V anno del Corso di Laurea A in Medicina e Chirurgia.
Presidente del Corso di Laurea in Infermieristica B.
Coordinatore della Scuola di Specializzazione in Malattie Infettive.
Coordinatore del Dottorato di Ricerca in Scienze Infettivologiche.
Membro del Comitato Scientifico e del Consiglio d'Amministrazione della Fonda¬zione "Eleonora Lorillard Spencer Cenci" della Sapienza Università di Roma.
Membro della Commissione Terapeutica Aziendale dell Azienda Policlinico Umberto I.
Membro del Comitato per il Controllo delle Infezioni Ospedaliere dell Azienda Policlinico Umberto I.

Date (da a)
1977 1994
Nome e indirizzo del datore di lavoro Dipartimento Malattie Infettive e Tropicali Sapienza Università di Roma
Tipo di azienda o settore Sapienza Università di Roma
Tipo di impiego Ricercatore Universitario Malattie Infettive

ISTRUZIONE E FORMAZIONE

Date (da a) 1982
Nome e tipo di istituto di istruzione o formazione Specializzazione
Principali materie / abilità professionali oggetto dello studio Malattie Infettive
Qualifica conseguita Specializzazione in Malattie Infettive

Date (da a) 1979
Nome e tipo di istituto di istruzione o formazione Specializzazione
Principali materie / abilità professionali oggetto dello studio Malattie Tropicali
Qualifica conseguita Specializzazione in Malattie Tropicali

Date (da a)
28/6/1974
Nome e tipo di istituto di istruzione o formazione Laurea
Principali materie / abilità professionali oggetto dello studio Medicina e Chirurgia
Qualifica conseguita Laurea in Medicina e Chirurgia

CAPACITÀ E COMPETENZE PERSONALI

PRIMA LINGUA italiano

ALTRE LINGUE

Inglese
Capacità di lettura Buono
Capacità di scrittura Buono
Capacità di espressione orale Buono

CAPACITÀ E COMPETENZE RELAZIONALI Responsabile di progetti di ricerca del MIUR e dell ISS; è inoltre sperimentatore principale in numerosi studi clinici nazionali ed internazionali sulla terapia antiretrovirale

INCARICHI SVOLTI IN ALTRI EVENTI FORMATIVI (ULTIMI 3 ANNI) Partecipazione come relatore o moderatore a numerosi congressi e convegni nazionali ed internazionali quali, a titolo di esempio, i Congressi SIMIT, ANLAIDS, ICAR, ecc.

ALTRE CAPACITÀ E COMPETENZE

E' autore di oltre 290 pubblicazioni in extenso riguardanti temi di Malattie Infettive e Immunologia appli¬cata alle malattie infettive e parassitarie pubblicate su riviste nazionali ed internazionali. E' stato inoltre relato¬re a numerosi congressi nazionali ed internazionali.
Oltre a numerose ricerche su argomenti di patologia infettiva, dedicate specialmente allo studio dell'idatidosi, delle salmonellosi, delle infezioni da micobatteri e delle epatiti virali, da più di 15 anni svolge una continuativa attività di ricerca nel campo della malattia da HIV e pato¬logie correlate. In particolare, sono stati approfonditi i seguenti argomenti:
patogenesi dell'infezione da HIV, con particolare riguardo ai markers prognostici di progressione;
manifestazioni neuro¬logiche HIV-correlate ed identificazione di markers liquorali di danno neurologico in corso di AIDS dementia complex;
studio degli aspetti patogenetici, immu¬nologici e diagnostici di alcune infezioni opportunistiche
monitoraggio virologico ed immunologico della terapia antiretrovirale;
studio dell immunità naturale in corso di infezione da HIV ed effetto dei farmaci antiretrovirali

NUMERO TOTALE DI LAVORI SCIENTIFICI Oltre 330 pubblicazioni su riviste peer reviewed

IMPACT FACTOR COMPLESSIVO >500

ALLEGATI Principali pubblicazioni scientifiche degli ultimi 5 anni

Roma, 25/02/2015

Autorizzo il trattamento dei dati personali
Roma, 25/02/2015

ALLEGATO - PUBBLICAZIONI DEGLI ULTIMI 5 ANNI

Fabbiani M, Di Giambenedetto S, Quiros-Roldan E, Latini A, Vullo V, Antinori A, Castagna A, Orofino G, Francisci D, Grilli E, Madeddu G, Grima P, Rusconi S, Del Pin B, Mondi A, Borghetti A, Focà E, Colafigli M, De Luca A, Cauda R. Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19808.
Cozzi-Lepri A, Antinori A, Bonora S, Cingolani A, Cassola G, Angarano G, Vullo V, Mussini C, Gori A, Maggiolo F, Castagna A; d Arminio Monforte on behalf of the ICONA Foundation Study, Antonella. An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19771.
D'Abramo A, Zingaropoli MA, Oliva A, D'Agostino C, Al Moghazi S, De Luca G, Iannetta M, Mastroianni CM, Vullo V. Immune Activation, Immunosenescence, and Osteoprotegerin as Markers of Endothelial Dysfunction in Subclinical HIV-Associated Atherosclerosis. Mediators Inflamm. 2014;2014:192594.
d'Ettorre G, Baroncelli S, Micci L, Ceccarelli G, Andreotti M, Sharma P, Fanello G, Fiocca F, Cavallari EN, Giustini N, Mallano A, Galluzzo CM, Vella S, Mastroianni CM, Silvestri G, Paiardini M, Vullo V. Reconstitution of Intestinal CD4 and Th17 T Cells in Antiretroviral Therapy Suppressed HIV-Infected Subjects: Implication for Residual Immune Activation from the Results of a Clinical Trial. PLoS One. 2014 Oct 23;9(10):e109791.
Milito C, Carello R, Fantauzzi A, Vullo V, Mezzaroma I. Streptococcus dysgalactiae subspecies equisimilis bacteraemia in an HIV-1 patient with HBV/HCV co-infections: case report and literature review. Infez Med. 2014 Sep;22(3):241-6.
Scorzolini L, Lichtner M, Iannetta M, Mengoni F, Russo G, Panni AS, Vasto M, Bove M, Villani C, Mastroianni CM, Vullo V. Sonication technique improves microbiological diagnosis in patients treated with antibiotics before surgery for prosthetic joint infections. New Microbiol. 2014 Jul;37(3):321-8.
Sauzullo I, Mastroianni CM, Mengoni F, Ermocida A, Mascia C, Salotti A, Falciano M, Vullo V. Long-term IFN- and IL-2 response for detection of latent tuberculosis infection in healthcare workers with discordant immunologic results. J Immunol Methods. 2014 Aug 8. pii: S0022-1759(14)00245-2.
Lichtner M, Cicconi P, Vita S, Cozzi-Lepri A, Galli M, Lo Caputo S, Saracino A, De Luca A, Moioli M, Maggiolo F, Marchetti G, Vullo V, d'Arminio Monforte A; for the ICONA Foundation Study. Cytomegalovirus Coinfection Is Associated With an Increased Risk of Severe Non-AIDS-Defining Events in a Large Cohort of HIV-Infected Patients. J Infect Dis. 2014 Jul 31.
d'Ettorre G, Ceccarelli G, Giustini N, Mastroianni CM, Silvestri G, Vullo V. Taming HIV-related inflammation with physical activity: a matter of timing. AIDS Res Hum Retroviruses. 2014 Oct;30(10):936-44.
Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, Kowalska JD, de Wit S, Law M, el Sadr W, Kirk O, Friis-Moller N, Monforte Ad, Phillips AN, Sabin CA, Lundgren JD; D:A:D Study Group. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet. 2014 Jul 19;384(9939):241-8.
Mocroft A, Ryom L, Begovac J, Monforte AD, Vassilenko A, Gatell J, Florence E, Ormaasen V, Kirk O, Lundgren JD; EuroSIDA in EuroCOORD. Deteriorating renal function and clinical outcomes in HIV-positive persons. AIDS. 2014 Mar 13;28(5):727-37.
Mocroft A, Reiss P, Rakhmanova A, Banhegyi D, Phillips AN, De Wit S, Ristola M, Lundgren JD, Grarup J, Kirk O; EuroSIDA in EuroCOORD. A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe. Infection. 2014 Aug;42(4):757-62.
Mastroianni CM, Lichtner M, Mascia C, Zuccalà P, Vullo V. Molecular mechanisms of liver fibrosis in HIV/HCV coinfection. Int J Mol Sci. 2014 May 26;15(6):9184-208.
Ermocida A, Mengoni F, Sauzullo I, Rossi R, Ajassa C, Lichtner M, Mastroianni CM, Vullo V. Extravirologic modulation of immune response by an NRTI-sparing antiretroviral regimen including darunavir and maraviroc. New Microbiol. 2014 Apr;37(2):225-9.
Sauzullo I, Mengoni F, Ermocida A, Massetti AP, D'Agostino C, Russo G, Salotti A, Falciano M, Vullo V, Mastroianni CM. Interferon- release assay in HIV-infected patients with active tuberculosis: impact of antituberculous drugs on host immune response. New Microbiol. 2014 Apr;37(2):153-61.
Scrivo R, Sauzullo I, Mengoni F, Riccieri V, Altieri AM, Cantoro L, Vullo V, Mastroianni CM, Valesini G. The role of interferon-gamma release assays in predicting the emergence of active tuberculosis in the setting of biological treatment: a case report and review of the literature. Clin Rheumatol. 2014 May 15.
Rota MC, Fontana S, Montaño-Remacha C, Scaturro M, Caporali MG, Vullo V, Scorzolini L, Ercole A, Ricci ML. Legionnaires' disease pseudoepidemic due to falsely positive urine antigen test results. J Clin Microbiol. 2014 Jun;52(6):2279-80.
Kamara DA, Ryom L, Ross M, Kirk O, Reiss P, Morlat P, Moranne O, Fux CA, Mocroft A, Sabin C, Lundgren JD, Smith CJ; D:A:D study Group. Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study. BMC Nephrol. 2014 Mar 25;15:51.
Fantauzzi A, Digiulio MA, Cavallari EN, d'Ettorre G, Vullo V, Mezzaroma I. Guillain Barrè syndrome in an HIV-1-infected patient after the beginning of combined antiretroviral therapy: an immune reconstitution inflammatory syndrome? New Microbiol. 2014 Jan;37(1):103-7.
Sauzullo I, Scrivo R, Mengoni F, Ermocida A, Coppola M, Valesini G, Vullo V, Mastroianni CM. Multifunctional flow cytometry analysis of CD4+ T cells as an immune biomarker for latent tuberculosis status in patients treated with TNF antagonists. Clin Exp Immunol. 2014 Feb 15.
A. Oliva, A. D Abramo, C. D Agostino, M. Iannetta, Maria T. Mascellino, C. Gallinelli, C. M. Mastroianni and V. Vullo. Synergistic activity and effectiveness of a double-carbapenem regimen in pandrug-resistant Klebsiella pneumoniae bloodstream infections. Journal of Antimicrobial Chemotherapy 2014 Feb 11.
Rossi R, Lichtner M, Iori F, Ermocida A, Mascia C, Mengoni F, Sauzullo I, Dini D, Mastroianni CM, Vullo V. Dendritic cells in blood and urine samples from bladder cancer patients undergoing BCG immunotherapy. Arch Ital Urol Androl. 2013 Dec 31;85(4):157-63.
D'Abramo A, D'Agostino C, Oliva A, Iannetta M, D'Ettorre G, Vullo F, Mancone M, Ciardi MR, Mastroianni CM, Vullo V. Early Atherosclerosis in HIV Infected Subjects on Suppressive Antiretroviral Treatment: Role of Osteoprotegerin. ISRN AIDS. 2013 Dec 5;2013:737083.
Falcone M, Russo A, Massimo M, Carriero G, Mazzesi G, Miraldi F, Pennacchi M, Pugliese F, Tritapepe L, Vullo V, Fedele F, Sardella G, Venditti M. Early, intermediate and late infectious complications after transcatheter or surgical aortic-valve replacement: a prospective cohort study. Clin Microbiol Infect. 2013 Nov 25.
Nelson Cavallari E, d'Ettorre G, Ceccarelli G, Serafini S, Pierangeli A, Impagnatiello A, Ascoli Bertoli T, Bianchi L, Antonelli G, Vullo V, Indinnimeo M. High prevalence of anal HPV infection among HIV-positive male subjects in the absence of anal intercourse. Sex Health. 2013 Nov;10(6):571.
Fabbiani M, Mondi A, Colafigli M, D'Ettorre G, Paoletti F, D'Avino A, Ciccarelli N, Sidella L, Murri R, Fortuna S, Vullo V, Cauda R, De Luca A, Di Giambenedetto S. Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study). Scand J Infect Dis. 2013 Oct 28.
Meini G, Rossetti B, Bianco C, Ceccherini-Silberstein F, Di Giambenedetto S, Sighinolfi L, Monno L, Castagna A, Rozera G, D'Arminio Monforte A, Zazzi M, De Luca A; on behalf of the ICONA Foundation Group.Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy. J Antimicrob Chemother. 2013 Oct 23.
Svicher V, Alteri C, Montano M, Nori A, D'Arrigo R, Andreoni M, Angarano G, Antinori A, Antonelli G, Allice T, Bagnarelli P, Baldanti F, Bertoli A, Borderi M, Boeri E, Bon I, Bruzzone B, Barresi R, Calderisi S, Callegaro AP, Capobianchi MR, Gargiulo F, Castelli F, Cauda R, Ceccherini-Silberstein F, Clementi M, Chirianni A, Colafigli M, D'Arminio Monforte A, De Luca A, Di Biagio A, Di Nicuolo G, Di Perri G, Di Santo F, Fadda G, Galli M, Gennari W, Ghisetti V, Costantini A, Gori A, Gulminetti R, Leoncini F, Maffongelli G, Maggiolo F, Maserati R, Mazzotta F, Meini G, Micheli V, Monno L, Mussini C, Nozza S, Paolucci S, Palù G, Parisi S, Parruti G, Pignataro AR, Quirino T, Re MC, Rizzardini G, Sanguinetti M, Santangelo R, Scaggiante R, Sterrantino G, Turriziani O, Vatteroni ML, Viscoli C, Vullo V, Zazzi M, Lazzarin A, Perno CF. Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group. Infection. 2013 Oct 22.
Scarpino M, Pinzone MR, Di Rosa M, Madeddu G, Focà E, Martellotta F, Schioppa O, Ceccarelli G, Celesia BM, d'Ettorre G,Vullo V, Berretta S, Cacopardo B, Nunnari G. Kidney disease in HIV-infected patients. Eur Rev Med Pharmacol Sci. 2013 Oct;17(19):2660-7.
Zaffiri L, d'Ettorre G, Ceccarelli G, Andreotti M, Marcellini S, Giustini N, Ascoli-Bartoli T, Mastroianni CM, Vella S, Vullo V. Recovery of Interleukin-17 Production from Interleukin-15-Stimulated CD4+ Mononuclear Cells in HIV-1-Infected Patients with Sustained Viral Suppression. J Interferon Cytokine Res. 2013 Oct 8.
Sauzullo I, Mengoni F, Marocco R, Potenza C, Skroza N, Tieghi T, Lichtner M, Vullo V, Mastroianni CM. Interferon- release assay for tuberculosis in patients with psoriasis treated with tumour necrosis factor antagonists: in vivo and in vitro analysis. Br J Dermatol. 2013 Nov;169(5):1133-40.
Grint D, Peters L, Schwarze-Zander C, Beniowski M, Pradier C, Battegay M, Jevtovic D, Soriano V, Lundgren JD, Rockstroh JK, Kirk O, Mocroft A; EuroSIDA in EuroCoord. Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA. HIV Med. 2013 Nov;14(10):614-23.
Bona R, Baroncelli S, D'Ettorre G, Andreotti M, Ceccarelli G, Filati P, Leone P, Blasi M, Michelini Z, Galluzzo CM, Mallano A, Vullo V, Cara A.Effects of raltegravir on 2-long terminal repeat circle junctions in HIV type 1 viremic and aviremic patients. AIDS Res Hum Retroviruses. 2013 Oct;29(10):1365-9.
Lapadula G, Cozzi-Lepri A, Marchetti G, Antinori A, Chiodera A, Nicastri E, Parruti G, Galli M, Gori A, Monforte Ad; ICONA Foundation Study.Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment. AIDS. 2013 Mar 13;27(5):769-79.
Iannetta M, Bellizzi A, Lo Menzo S, Anzivino E, D'Abramo A, Oliva A, D'Agostino C, d'Ettorre G, Pietropaolo V, Vullo V, Ciardi MR. HIV-associated progressive multifocal leukoencephalopathy: longitudinal study of JC virus non-coding control region rearrangements and host immunity. J Neurovirol. 2013 Jun;19(3):274-9.
CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use. Mocroft A, Phillips AN, Gatell J, Horban A, Ledergerber B, Zilmer K, Jevtovic D, Maltez F, Podlekareva D, Lundgren JD; EuroSIDA study in EuroCOORD. AIDS. 2013 Mar 27;27(6):907-18.
Pinzone MR, Di Rosa M, Malaguarnera M, Madeddu G, Focà E, Ceccarelli G, d'Ettorre G, Vullo V, Fisichella R, Cacopardo B, Nunnari G.Vitamin D deficiency in HIV infection: an underestimated and undertreated epidemic. Eur Rev Med Pharmacol Sci. 2013 May;17(9):1218-32. Review.
Eron JJ, Cooper DA, Steigbigel RT, Clotet B, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Markowitz M, Yeni P, Loutfy MR, Lazzarin A, Lennox JL, Strohmaier KM, Wan H, Barnard RJ, Nguyen BY, Teppler H; BENCHMRK Study Teams.Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. Lancet Infect Dis. 2013 Jul;13(7):587-96. doi: 10.1016/S1473-3099(13)70093-8. Epub 2013 May 7.
D'Ettorre G, Lo Presti A, Gori C, Cella E, Bertoli A, Vullo V, Perno CF, Ciotti M, Foley BT, Ciccozzi M; HIV-2 Study Group. .An HIV type 2 case series in Italy: a phylogenetic analysis. AIDS Res Hum Retroviruses. 2013 Sep;29(9):1254-9.
Grint D, Peters L, Reekie J, Soriano V, Kirk O, Knysz B, Suetnov O, Lazzarin A, Ledergerber B, Rockstroh JK, Mocroft A; EuroSIDA in EuroCoord (European Coordinating Committee for the Integration of Ongoing Coordination Actions Related to Clinical and Epidemiological HIV Research). Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy. HIV Med. 2013 Jul;14(6):370-8.
Rotger M, Glass TR, Junier T, Lundgren J, Neaton JD, Poloni ES, van 't Wout AB, Lubomirov R, Colombo S, Martinez R, Rauch A, Günthard HF, Neuhaus J, Wentworth D, van Manen D, Gras LA, Schuitemaker H, Albini L, Torti C, Jacobson LP, Li X, Kingsley LA, Carli F, Guaraldi G, Ford ES, Sereti I, Hadigan C, Martinez E, Arnedo M, Egaña-Gorroño L, Gatell JM, Law M, Bendall C, Petoumenos K, Rockstroh J, Wasmuth JC, Kabamba K, Delforge M, De Wit S, Berger F, Mauss S, de Paz Sierra M, Losso M, Belloso WH, Leyes M, Campins A, Mondi A, De Luca A, Bernardino I, Barriuso-Iglesias M, Torrecilla-Rodriguez A, Gonzalez-Garcia J, Arribas JR, Fanti I, Gel S, Puig J, Negredo E, Gutierrez M, Domingo P, Fischer J, Fätkenheuer G, Alonso-Villaverde C, Macken A, Woo J, McGinty T, Mallon P, Mangili A, Skinner S, Wanke CA, Reiss P, Weber R, Bucher HC, Fellay J, Telenti A, Tarr PE; MAGNIFICENT Consortium; INSIGHT; Swiss HIV Cohort Study. Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons. Clin Infect Dis. 2013 Jul;57(1):112-21.
Oliva A, Lichtner M, Mascellino MT, Iannetta M, Ialungo AM, Tadadjeu Mewamba S, Pavone P, Mengoni F, Mastroianni CM,Vullo V. Study of methicillin-resistant Staphylococcus aureus (MRSA) carriage in a population of HIV-negative migrants and HIV-infected patients attending an outpatient clinic in Rome.Ann Ig. 2013 Mar-Apr;25(2):99-107.
Matusali G, Tchidjou HK, Pontrelli G, Bernardi S, D'Ettorre G,Vullo V, Buonomini AR, Andreoni M, Santoni A, Cerboni C, Doria M.. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells. FASEB J. 2013 Jun;27(6):2440-50.
Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, Ross M, Fux CA, Morlat P, Moranne O, Smith C, Lundgren JD; D:A:D Study Group. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis. 2013 May 1;207(9):1359-69.
De Luca A, Dunn D, Zazzi M, Camacho R, Torti C, Fanti I, Kaiser R, Sönnerborg A, Codoñer FM, Van Laethem K, Vandamme AM, Bansi L, Ghisetti V, van de Vijver DA, Asboe D, Prosperi MC, Di Giambenedetto S; SEHERE collaboration in Chain. .Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. J Infect Dis. 2013 Apr 15;207(8):1216-20
Ceccarelli G, d'Ettorre G, Vullo V. The challenge of cardiovascular diseases in HIV-positive patients: it's time for redrawing the maps of cardiovascular risk? Int J Clin Pract. 2013 Jan;67(1):1-3.
Scrivo R, Sauzullo I, Mengoni F, Priori R, Coppola M, Iaiani G, DI Franco M, Vullo V, Mastroianni CM, Valesini G. Mycobacterial interferon- release variations during longterm treatment with tumor necrosis factor blockers: lack of correlation with clinical outcome. J Rheumatol. 2013 Feb;40(2):157-65.
Oliva A, Nguyen BL, Mascellino MT, D'Abramo A, Iannetta M, Ciccaglioni A, Vullo V, Mastroianni CM.Sonication of explanted cardiac implants improves microbial detection in cardiac device infections. J Clin Microbiol. 2013 Feb;51(2):496-502.
Ceccarelli G, d'Ettorre G, Riccardo F, Ceccarelli C, Chiaretti M, Picciarella A, Pacifici LE, Vullo V. Urinary schistosomiasis in asylum seekers in Italy: an emergency currently undervalued. J Immigr Minor Health. 2013 Aug;15(4):846-50.
Baroncelli S, Mezzaroma I, Fantauzzi A, Galluzzo CM, Antoni AD,Vullo V, Francisci D, Ladisa N, Vivarelli A, Cirioni O, Sighinolfi L, Weimer LE, Fragola V, Fidanza R, Cara A, Palmisano L .No evidence of autoimmune disorders in antiretroviral-experienced HIV-1-infected individuals after long-term treatment with raltegravir. Antivir Ther. 2013;18(3):321-7.
Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection. Weimer LE, Fragola V, Floridia M, Guaraldi G, Ladisa N, Francisci D, Bellagamba R, Degli Antoni A, Parruti G, Giacometti A, Manconi PE, Vivarelli A, D'Ettorre G, Mura MS, Cicalini S, Preziosi R, Sighinolfi L, Verucchi G, Libertone R, Tavio M, Sarmati L, Bucciardini R; ISS-NIA Study Group. J Antimicrob Chemother. 2013 Jan;68(1):193-9.
Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort. Di Biagio A, Prinapori R, Giannarelli D, Maggiolo F, Di Giambenedetto S, Borghi V, Penco G, Cicconi P, Francisci D, Sterrantino G, Zoncada A, Monno L, Capetti A, Giacometti A; ARCA Collaborative Group. J Antimicrob Chemother. 2013 Jan;68(1):200-5.
D'Ettorre G, Douek D, Paiardini M, Ceccarelli G, Vullo V. Microbial translocation and infectious diseases: what is the link? Int J Microbiol. 2012;2012:356981.
Baroncelli S, Mezzaroma I, Fantauzzi A, Galluzzo MC, Antoni AD, Vullo V, Francisci D, Ladisa N, Vivarelli A, Cirioni O, Sighinolfi L, Weimer LE, Fragola V, Fidanza R, Cara A, Palmisano L. No evidence of autoimmune disorders in antiretroviral-experienced HIV-1-infected subjects after long-term treatment with raltegravir. Antivir Ther. 2012 Oct 9.
Reekie J, Kowalska JD, Karpov I, Rockstroh J, Karlsson A, Rakhmanova A, Horban A, Kirk O, Lundgren JD, Mocroft A; EuroSIDA in EuroCoord. Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: the EuroSIDA study. PLoS One. 2012;7(7):e41673.
Scrivo R, Sauzullo I, Mengoni F, Iaiani G, Vestri AR, Priori R, Di Filippo E, Di Franco M, Spinelli FR, Vullo V, Mastroianni CM, Valesini G. Serial interferon- release assays for screening and monitoring of tuberculosis infection during treatment with biologic agents. Clin Rheumatol. 2012 Aug 5
Bucciardini R, D'Ettorre G, Baroncelli S, Ceccarelli G, Parruti G, Weimer LE, Fragola V, Galluzzo CM, Pirillo MF, Lucattini S, Bellagamba R, Francisci D, Ladisa N, Degli Antoni A, Guaraldi G, Manconi PE, Vullo V, Preziosi R, Cirioni O, Verucchi G, Floridia M; ISS-NIA study group. Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors. Int J STD AIDS. 2012 Jul;23(7):459-63..
Scientific Coordination Committee, Marcotullio S, Andreoni M, Antinori A, d'Arminio Monforte A, Di Perri G, Galli M, Ippolito G, Perno CF, Rizzardini G, Lazzarin A; Rapporteur Committee, Cinque P, Fares G, Foglia E, Gervasoni C, Murri R, Nozza S, Rusconi S. The Less Drugs Regimens (LDRs) therapy approach in HIV-1: an Italian expert panel perspective for the long-term management of HIV-1 infection. New Microbiol. 2012 Jul;35(3):259-77. Epub 2012 Jun 30. PubMed PMID: 22842596.
Marcone V, Recine N, Gallinelli C, Nicosia R, Lichtner M, Degener AM, Chiarini F, Calzolari E, Vullo V. Epidemiology of Chlamydia trachomatis endocervical infection in a previously unscreened population in Rome, Italy, 2000 to 2009. Euro Surveill. 2012 Jun 21;17(25).
De Luca A, de Gaetano Donati K, Cozzi-Lepri A, Colafigli M, De Curtis A, Capobianchi MR, Antinori A, Giacometti A, Magnani G, Vullo V, Cauda R, Iacoviello L, d'Arminio Monforte A; ICoNA Foundation Study Group. Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: a longitudinal study. J Acquir Immune Defic Syndr. 2012 Jul 1;60(3):e98-101.
Bibas M, Trotta MP, Cozzi-Lepri A, Lorenzini P, Pinnetti C, Rizzardini G, Angarano G, Caramello P, Sighinolfi L, Mastroianni CM, Mazzarello G, Di Caro A, mDi Giacomo C, d'Arminio Monforte A, Antinori A; ICONA Foundation Study Group. Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy. Am J ,Hematol. 2012 Aug;87(8):749-53.
Antinori A, Marcotullio S, Ammassari A, Andreoni M, Angarano G, Armignacco O, ,Carosi G, Cinque P, d'Arminio Monforte A, Di Perri G, Ensoli B, Floridia M, Galli M, Mastroianni C, Matteelli A, Mazzotta F, Moroni M, Pal G, Puoti M, Puro V, Rizzardini G, Sagnelli E, Vella S, Vullo V, Lazzarin A; Italian HIV Guidelines Working Group. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. New Microbiol. 2012 Apr;35(2):113-59.
Colafigli M, Torti C, Trecarichi EM, Albini L, Rosi A, Micheli V, Manca N Penco G, Bruzzone B, Punzi G, Corsi P, Parruti G, Bagnarelli P, Monno L, Gonnelli A, Cauda R, Di Giambenedetto S; ARCA, UCSC and Brescia HIV resistance study groups. Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010. Clin Microbiol Infect. 2012 Aug;18(8):E299-304.
Mammone A, Pezzotti P, Angeletti C, Orchi N, Carboni A, Navarra A, Sciarrone MR, Sias C, Puro V, Guasticchi G, Ippolito G, Borgia P, Girardi E; SENDIH Study Group. HIV incidence estimate combining HIV/AIDS surveillance, testing history information and HIV test to identify recent infections in Lazio, Italy. BMC Infect Dis. 2012 Mar 20;12:65.
Svicher V, Alteri C, Montano M, D'Arrigo R, Andreoni M, Angarano G, Antinori A, Antonelli G, Allice T, Bagnarelli P, Baldanti F, Bertoli A, Borderi M, Boeri E, Bon I, Bruzzone B, Callegaro AP, Capobianchi MR, Carosi G, Cauda R, Ceccherini-Silberstein F, Clementi M, Chirianni A, Colafigli M, D'Arminio Monforte A, De Luca A, Di Biagio A, Di Nicuolo G, Di Perri G, Di Pietro M, Di Santo F, Fabeni L, Fadda G, Galli M, Gennari W, Ghisetti V, Giacometti A, Gori C, Gori A, Gulminetti R, Leoncini F, Maffongelli G, Maggiolo F, Manca G, Gargiulo F, Martinelli C, Maserati R, Mazzotta F, Meini G, Micheli V, Monno L, Mussini C, Narciso P, Nozza S, Paolucci S, Pal G, Parisi S, Parruti G, Pignataro AR, Pollicita M, Quirino T, Re MC, Rizzardini G, Santangelo R, Scaggiante R, Sterrantino G, Turriziani O, Vatteroni ML, Vecchi L, Viscoli C, Vullo V, Zazzi M, Lazzarini A, Perno CF; DIVA group. Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group. New Microbiol. 2012 Jan;35(1):17-25.
Nozza S, Canducci F, Galli L, Cozzi-Lepri A, Capobianchi MR, Ceresola ER, Narciso P, Libertone R, Castelli P, Moioli M, D'Arminio Monforte A, Castagna A; ICONA Foundation. Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naive patients with high CD4 counts. J Antimicrob Chemother. 2012 May;67(5):1224-7.
Sterrantino G, Zaccarelli M, Colao G, Baldanti F, Di Giambenedetto S, Carli T, Maggiolo F, Zazzi M; ARCA Database Study Group. Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis. Infection. 2012 Jun;40(3):311-8.
Turriziani O, Montagna C, Falasca F, Bucci M, Russo G, Lichtner M, Sobze MS, Vullo V, Pistello M, Antonelli G. Analysis of the Integrase Gene from HIV Type 1-Positive Patients Living in a Rural Area of West Cameroon. AIDS Res Hum Retroviruses. 2012 Mar 2.
Gramegna P, Latronico T, Branà MT, Di Bari G, Mengoni F, Belvisi V, Mascellino MT, Lichtner M, Vullo V, Mastroianni CM, Liuzzi GM. In vitro downregulation of matrix metalloproteinase-9 in rat glial cells by CCR5 antagonist maraviroc: therapeutic implication for HIV brain infection. PLoS One. 2011;6(12):e28499.
Kowalska JD, Reekie J, Mocroft A, Reiss P, Ledergerber B, Gatell J, d'Arminio Monforte A, Phillips A, Lundgren JD, Kirk O; EuroSIDA study group. Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy. AIDS. 2012 Jan 28;26(3):315-23.
d'Ettorre G, Andreotti M, Ceccarelli G, Galluzzo CM, Mallano A, Massetti AP, Tierno F, Stella S, Amici R, Vella S, Mastroianni CM, Vullo V. The role of IL-15 in challenging Acquired Immunodeficiency Syndrome. Cytokine. 2012 Jan;57(1):54-60.
Molina JM, Lamarca A, Andrade-Villanueva J, Clotet B, Clumeck N, Liu YP, Zhong L, Margot N, Cheng AK, Chuck SL; Study 145 Team. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis. 2012 Jan;12(1):27-35.
d'Ettorre G, Francone M, Mancone M, Ceccarelli G, Ascarelli A, Vullo F, Baroncelli S, Galluzzo MC, Catalano C, Strano S, Fedele F, Mastroianni C, Palmisano L, Vullo V. Significant coronary stenosis detected by coronary computed angiography in asymptomatic HIV infected subjects. J Infect. 2012 Jan;64(1):82-8
Esposito A, Floridia M, d'Ettorre G, Pastori D, Fantauzzi A, Massetti P, Ceccarelli G, Ajassa C, Vullo V, Mezzaroma I. Rate and determinants of treatment response to different antiretroviral combination strategies in subjects presenting at HIV-1 diagnosis with advanced disease. BMC Infect Dis. 2011 Dec 14;11:341.
Mastroianni CM, Lichtner M, Citton R, Del Borgo C, Rago A, Martini H, Cimino G, Vullo V. Current trends in management of hepatitis B virus reactivation in the biologic therapy era. World J Gastroenterol. 2011 Sep 14;17(34):3881-7. Review.
d'Arminio Monforte A, Cozzi-Lepri A, Girardi E, Castagna A, Mussini C, Di Giambenedetto S, Galli M, Cassola G, Vullo V, Quiros-Roldan E, Lo Caputo S, Antinori A; Icona Foundation Study Group. Late presenters in new HIV diagnoses from an Italian cohort of HIV-infected patients: prevalence and clinical outcome. Antivir Ther. 2011;16(7):1103-12.
Rossi R, Lichtner M, De Rosa A, Sauzullo I, Mengoni F, Massetti AP, Mastroianni CM, Vullo V. In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells. Clin Exp Immunol. 2011 Nov;166(2):184-90.
Reekie J, Gatell JM, Yust I, Bakowska E, Rakhmanova A, Losso M, Krasnov M, Francioli P, Kowalska JD, Mocroft A; EuroSIDA in EuroCoord. Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata. AIDS. 2011 Nov 28;25(18):2259-68.
Paredes R, Puertas MC, Bannister W, Kisic M, Cozzi-Lepri A, Pou C, Bellido R, Betancor G, Bogner J, Gargalianos P, Bánhegyi D, Clotet B, Lundgren J, Menéndez-Arias L, Martinez-Picado J; EuroSIDA Study Group. A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy. J Infect Dis. 2011 Sep 1;204(5):741-52.
Vescini F, Cozzi-Lepri A, Borderi M, Re MC, Maggiolo F, De Luca A, Cassola G, Vullo V, Carosi G, Antinori A, Tozzi V, Monforte AD; Icona Foundation Study Group. Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort. J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):163-72.
Camoni L, Dal Conte I, Regine V, Colucci A, Chiriotto M, Vullo V, Sebastiani M, Cordier L, Beretta R, Fiore JR, Tateo M, Affronti M, Cassarà G, Suligoi B. Sexual behaviour reported by a sample of Italian MSM before and after HIV diagnosis. Ann Ist Super Sanita. 2011;47(2):214-9.
Prosperi MC, Di Giambenedetto S, Fanti I, Meini G, Bruzzone B, Callegaro A, Penco G, Bagnarelli P, Micheli V, Paolini E, Di Biagio A, Ghisetti V, Di Pietro M, Zazzi M, De Luca A; ARCA cohort. A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen. BMC Med Inform Decis Mak. 2011 Jun 14;11:40.
Sauzullo I, Massetti AP, Mengoni F, Rossi R, Lichtner M, Ajassa C, Vullo V, Mastroianni CM. Influence of previous tuberculin skin test on serial IFN- release assays. Tuberculosis (Edinb). 2011 Jul;91(4):322-6.
Lichtner M, Mastroianni CM, Rossi R, Russo G, Belvisi V, Marocco R, Mascia C, Del Borgo C, Mengoni F, Sauzullo I, d'Ettorre G, D'Agostino C, Massetti AP, Vullo V. Severe and persistent depletion of circulating plasmacytoid dendritic cells in patients with 2009 pandemic H1N1 infection. PLoS One. 2011;6(5):e19872
33: Prosperi MC, Mackie N, Di Giambenedetto S, Zazzi M, Camacho R, Fanti I, Torti C, Sönnerborg A, Kaiser R, Codoñer FM, Van Laethem K, Bansi L, van de Vijver DA, Geretti AM, De Luca A; SEHERE consortium. Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. J Antimicrob Chemother. 2011 Aug;66(8):1886-96
Antinori A, Marcotullio S, Ammassari A, Andreoni M, Angarano G, Carosi G, Cinque P, d'Arminio Monforte A, Di Perri G, Ensoli B, Ferrazzi E, Galli M, Mastroianni C, Matteelli A, Mazzotta F, Moroni M, Palù G, Puoti M, Puro V, Rizzardini G, Sagnelli E, Suter F, Vella S, Lazzarin A; Italian HIV Guidelines Working Group. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. New Microbiol. 2011 Apr;34(2):109-46.
Prosperi MC, Ciccozzi M, Fanti I, Saladini F, Pecorari M, Borghi V, Di Giambenedetto S, Bruzzone B, Capetti A, Vivarelli A, Rusconi S, Re MC, Gismondo MR, Sighinolfi L, Gray RR, Salemi M, Zazzi M, De Luca A; ARCA collaborative group. A novel methodology for large-scale phylogeny partition. Nat Commun. 2011;2:321.
Kruk A, Bannister W, Podlekareva DN, Chentsova NP, Rakhmanova AG, Horban A, Domingo P, Mocroft A, Lundgren JD, Kirk O; EuroSIDA study group. Tuberculosis among HIV-positive patients across Europe: changes over time and risk factors. AIDS. 2011 Jul 31;25(12):1505-13.
Ceccarelli G, d'Ettorre G, Vullo V. Purulent Meningitis as an Unusual Presentation of Staphylococcus aureus Endocarditis: A Case Report and Literature Review. Case Report Med. 2011;2011:735265. Epub 2011 Mar 28.
Viard JP, Souberbielle JC, Kirk O, Reekie J, Knysz B, Losso M, Gatell J, Pedersen C, Bogner JR, Lundgren JD, Mocroft A; EuroSIDA Study Group. Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. AIDS. 2011 Jun 19;25(10):1305-15.
Marchetti G, Cozzi-Lepri A, Merlini E, Bellistrì GM, Castagna A, Galli M, Verucchi G, Antinori A, Costantini A, Giacometti A, di Caro A, D'arminio Monforte A; ICONA Foundation Study Group. Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. AIDS. 2011 Jul 17;25(11):1385-94.
Kowalska JD, Mocroft A, Ledergerber B, Florence E, Ristola M, Begovac J, Sambatakou H, Pedersen C, Lundgren JD, Kirk O; Eurosida Study Group. A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: results from the EuroSIDA study. HIV Clin Trials. 2011 Mar-Apr;12(2):109-17.
d'Ettorre G, Forcina G, Ceccarelli G, Andreotti M, Andreoni C, Rizza C, Massetti AP, Sarmati L, Mastroianni CM, Vella S, Andreoni M, Vullo V. Adherence and genotypic drug resistance mutations in HIV-1-infected patients failing current antiretroviral therapy. J Chemother. 2011 Feb;23(1):24-7.
d'Ettorre G, Paiardini M, Zaffiri L, Andreotti M, Ceccarelli G, Rizza C, Indinnimeo M, Vella S, Mastroianni CM, Silvestri G, Vullo V. HIV persistence in the gut mucosa of HIV-infected subjects undergoing antiretroviral therapy correlates with immune activation and increased levels of LPS. Curr HIV Res. 2011 Apr;9(3):148-53. PubMed PMID: 21457131.
Bannister WP, Cozzi-Lepri A, Kjær J, Clotet B, Lazzarin A, Viard JP, Kronborg G, Duiculescu D, Beniowski M, Machala L, Phillips A; EuroSIDA group. Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy. J Antimicrob Chemother. 2011 Apr;66(4):901-11.
Parisi SG, Andreoni C, Sarmati L, Boldrin C, Buonomini AR, Andreis S, Scaggiante R, Cruciani M, Bosco O, Manfrin V, d'Ettorre G, Mengoli C, Vullo V, Palù G, Andreoni M. HIV coreceptor tropism in paired plasma, peripheral blood mononuclear cell, and cerebrospinal fluid isolates from antiretroviral-naïve subjects. J Clin Microbiol. 2011 Apr;49(4):1441-5.
Ceccarelli G, d'Ettorre G, Marchetti F, Rizza C, Mastroianni CM, Carlesimo B, Vullo V. Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature. J Med Case Rep. 2011 Feb 17;5:70.
d'Ettorre G, Paiardini M, Ceccarelli G, Silvestri G, Vullo V. HIV-associated immune activation: from bench to bedside. AIDS Res Hum Retroviruses. 2011 Apr;27(4):355-64. doi: 10.1089/aid.2010.0342. Epub 2011 Mar 8. Review.
Ceccarelli G, d'Ettorre G, Mancone M, Francone M, Vullo V. Accelerated coronary atherosclerosis after execution of percutaneous coronary intervention in patient with HIV/HCV coinfection: case report and review of the literature. Cardiovasc Revasc Med. 2011 Jul-Aug;12(4):262-5
Torti C, d'Arminio-Monforte A, Pozniak AL, Lapadula G, Cologni G, Antinori A, De Luca A, Mussini C, Castagna A, Cicconi P, Minoli L, Costantini A, Carosi G, Liang H, Cesana BM; MASTER, Chelsea & Westminster, ICONA, Modena and S. Raffaele HIV Cohorts. Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI. BMC Infect Dis. 2011 Jan 25;11:23.
Gianotti N, Galli L, Zazzi M, Ghisetti V, Bonora S, Micheli V, Meraviglia P, Corsi P, Bruzzone B, Menzo S, Di Giambenedetto S, De Luca A, Filice G, Penco G, Castagna A; ARCA database initiative. No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy. J Med Virol. 2011 Mar;83(3):391-8.
Indinnimeo M, d'Ettorre G, Fiore A, Ceccarelli G, Ciardi A, Degener AM, Moschella CM, Izzo L, Izzo S, Antonelli G, D'Angeli I, Vullo V. Diagnosis of anal human papillomavirus infection: polymerase chain reaction or cytology? Int J Infect Dis. 2011 Apr;15(4):e232-5.
Reekie J, Reiss P, Ledergerber B, Sedlacek D, Parczewski M, Gatell J, Katlama C, Fätkenheuer G, Lundgren JD, Mocroft A; EuroSIDA study group. A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study. HIV Med. 2011 May;12(5):259-68
Falcone M, Massetti AP, Russo A, Vullo V, Venditti M. Invasive aspergillosis in patients with liver disease. Med Mycol. 2011 May;49(4):406-13.
Prosperi MC, Cozzi-Lepri A, Antinori A, Cassola G, Torti C, Ursitti MA, Pellizzer GP, Giacometti A, d'Arminio Monforte A, De Luca A; Icona Foundation Study Group. Favourable evolution of virological and immunological profiles in treated and untreated patients in Italy in the period 1998-2008. HIV Med. 2011 Mar;12(3):174-82.
Tordato F, Cozzi Lepri A, Cicconi P, De Luca A, Antinori A, Colangeli V, Castagna A, Nasta P, Ladisa N, Giacometti A, d'Arminio Monforte A, Gori A; ICONA Foundation Study Group. Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure. HIV Med. 2011 Jan;12(1):4-13.
Prosperi MC, Zazzi M, Punzi G, Monno L, Colao G, Corsi P, Di Giambenedetto S, Meini G, Ghisetti V, Bonora S, Pecorari M, Gismondo MR, Bagnarelli P, Carli T, De Luca A; ARCA Collaborative Group. Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice. J Med Virol. 2010 Dec;82(12):1996-2003.
Svicher V, D'Arrigo R, Alteri C, Andreoni M, Angarano G, Antinori A, Antonelli G, Bagnarelli P, Baldanti F, Bertoli A, Borderi M, Boeri E, Bonn I, Bruzzone B, Callegaro AP, Cammarota R, Canducci F, Ceccherini-Silberstein F, Clementi M, Monforte AD, De Luca A, Di Biagio A, Di Gianbenedetto S, Di Perri G, Di Pietro M, Fabeni L, Fadda G, Galli M, Gennari W, Ghisetti V, Giacometti A, Gori A, Leoncini F, Maggiolo F, Maserati R, Mazzotta F, Micheli V, Meini G, Monno L, Mussini C, Nozza S, Paolucci S, Parisi S, Pecorari M, Pizzi D, Quirino T, Re MC, Rizzardini G, Santangelo R, Soria A, Stazi F, Sterrantino G, Turriziani O, Viscoli C, Vullo V, Lazzarin A, Perno CF; OSCAR Study Group. Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. New Microbiol. 2010 Jul;33(3):195-206.
Oliva A, Belvisi V, Iannetta M, Andreoni C, Mascellino MT, Lichtner M, Vullo V, Mastroianni CM. Pacemaker lead endocarditis due to multidrug-resistant Corynebacterium striatum detected with sonication of the device. J Clin Microbiol. 2010 Dec;48(12):4669-71. Epub 2010 Oct 13. PubMed PMID: 20943861;
Arlotti M, Grossi P, Pea F, Tomei G, Vullo V, De Rosa FG, Di Perri G, Nicastri E, Lauria FN, Carosi G, Moroni M, Ippolito G; GISIG (Gruppo Italiano di Studio sulle Infezioni Gravi) Working Group on Brain Abscesses. Consensus document on controversial issues for the treatment of infections of the central nervous system: bacterial brain abscesses. Int J Infect Dis. 2010 Oct;14 Suppl 4:S79-92.
Trullas JC, Mocroft A, Cofan F, Tourret J, Moreno A, Bagnis CI, Fux CA, Katlama C, Reiss P, Lundgren J, Gatell JM, Kirk O, Miró JM; EuroSIDA Investigators. Dialysis and renal transplantation in HIV-infected patients: a European survey. J Acquir Immune Defic Syndr. 2010 Dec 15;55(5):582-9.
d'Ettorre G, Barbarini G, Corti F, Gobber M, Pastecchia C, Ricci GL, Siciliano M, Annicchiarico BE, Vullo V. Seroconversion of HBsAg in HBeAg positive and HBeAg negative patients with chronic HBV treated with entecavir: a case series. Eur Rev Med Pharmacol Sci. 2010 Jun;14(6):551-4.
Mocroft A, Reiss P, Gasiorowski J, Ledergerber B, Kowalska J, Chiesi A, Gatell J, Rakhmanova A, Johnson M, Kirk O, Lundgren J; EuroSIDA Study Group. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr. 2010 Oct;55(2):262-70.
Reekie J, Kosa C, Engsig F, Monforte A, Wiercinska-Drapalo A, Domingo P, Antunes F, Clumeck N, Kirk O, Lundgren JD, Mocroft A; EuroSIDA Study Group. Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. Cancer. 2010 Nov 15;116(22):5306-15.
Rossi R, Lichtner M, Sauzullo I, Mengoni F, Marocco R, Massetti AP, Mastroianni CM, Vullo V. Downregulation of leukocyte migration after treatment with CCR5 antagonist maraviroc. J Acquir Immune Defic Syndr. 2010 Aug;54(5):e13-4.
Trotta MP, Cozzi-Lepri A, Ammassari A, Vecchiet J, Cassola G, Caramello P, Vullo V, Soscia F, Chiodera A, Ladisa N, Abeli C, Cauda R, Buonuomi AR, Antinori A, d'Arminio Monforte A; ICONA Foundation Study. Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures. Clin Infect Dis. 2010 Aug 15;51(4):456-64.
Richetta AG, Lichtener M, Mattozzi C, Miccoli A, Giancristoforo S, D'Epiro S, Vullo V, Calvieri S. Fusariosis and skin T cell lymphoma: concomitant more than a differential diagnosis. Clin Ter. 2010;161(3):265-7.
Sauzullo I, Mengoni F, Scrivo R, Valesini G, Potenza C, Skroza N, Marocco R, Lichtner M, Vullo V, Mastroianni CM. Evaluation of QuantiFERON-TB Gold In-Tube in human immunodeficiency virus infection and in patient candidates for anti-tumour necrosis factor-alpha treatment. Int J Tuberc Lung Dis. 2010 Jul;14(7):834-40.
d'Ettorre G, Marchetti F, Ceccarelli G, Gizzi F, Tierno F, Falcone M, Venditti M, Carlesimo B, Vullo V. Surgical debridement with muscle flap transposition and systemic teicoplanin therapy for infected hip arthroplasty. Hip Int. 2010 Apr-Jun;20(2):255-7
Friis-Møller N, Thiébaut R, Reiss P, Weber R, Monforte AD, De Wit S, El-Sadr W, Fontas E, Worm S, Kirk O, Phillips A, Sabin CA, Lundgren JD, Law MG; DAD study group. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil. 2010 Oct;17(5):491-501.
Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, Gatell J, Phillips AN, Ledergerber B, Lundgren JD; EuroSIDA Study Group. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS. 2010 Jul 17;24(11):1667-78.
Sarmati L, Parisi SG, Andreoni C, Nicastri E, Buonomini AR, Boldrin C, Dori L, Montano M, Tommasi C, Andreis S, Vullo V, Palù G, Andreoni M. Switching of inferred tropism caused by HIV during interruption of antiretroviral therapy. J Clin Microbiol. 2010 Jul;48(7):2586-8.
Malan N, Su J, Mancini M, Yang R, Wirtz V, Absalon J, McGrath D; CASTLE Study Team. Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study. AIDS Care. 2010 Jun;22(6):677-86.
d'Ettorre G, Zaffiri L, Ceccarelli G, Mastroianni CM, Vullo V. The role of HIV-DNA testing in clinical practice. New Microbiol. 2010 Jan;33(1):1-11.
Baroncelli S, Villani P, Weimer LE, Ladisa N, Francisci D, Tommasi C, Vullo V, Preziosi R, Cicalini S, Cusato M, Galluzzo C, Floridia M, Regazzi M; ISS-NIA Group. Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration. Ann Pharmacother. 2010 May;44(5):838-43. Epub 2010 Apr 6.
Prosperi MC, Cozzi-Lepri A, Castagna A, Mussini C, Murri R, Giacometti A, Torti C, Costantini A, Narciso P, Ghinelli F, Antinori A, d'Arminio Monforte A; Icona Foundation Study Group. Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study. Clin Infect Dis. 2010 May 1;50(9):1316-21.
Reekie J, Mocroft A, Ledergerber B, Beniowski M, Clotet B, van Lunzen J, Chiesi A, Pradier C, Machala L, Lundgren JD; EuroSIDA Study Group. History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change. HIV Med. 2010 Aug;11(7):469-78. Epub 2010 Feb 22.
D'Agostino C, Scorzolini L, Massetti AP, Carnevalini M, d'Ettorre G, Venditti M, Vullo V, Orsi GB. A seven-year prospective study on spondylodiscitis: epidemiological and microbiological features. Infection. 2010 Apr;38(2):102-7. Epub 2010 Feb 27.
Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Katlama C, Markowitz M, Yeni P, Loutfy MR, Lazzarin A, Lennox JL, Clotet B, Zhao J, Wan H, Rhodes RR, Strohmaier KM, Barnard RJ, Isaacs RD, Nguyen BY; BENCHMRK Study Teamsa. Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis. 2010 Feb 15;50(4):605-12.
Soriano V, Mocroft A, Peters L, Rockstroh J, Antunes F, Kirkby N, de Wit S, Monforte A, Flisiak R, Lundgren J; EuroSIDA. Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. J Antimicrob Chemother. 2010 Mar;65(3):548-55.
Worm SW, Friis-Møller N, Bruyand M, D'Arminio Monforte A, Rickenbach M, Reiss P, El-Sadr W, Phillips A, Lundgren J, Sabin C; D:A:D study group. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. AIDS. 2010 Jan 28;24(3):427-35.
Russo G, Lichtner M, Carnevalini M, Mascellino MT, Mengoni F, Oliva A, Miccoli GA, Iannetta M, Trinchieri V, Massetti AP, Mastroianni CM, Vullo V. Primary retroperitoneal abscesses due to Rhodococcus equi in a patient with severe nephrotic syndrome: successful antibiotic treatment with linezolid and tigecycline. Int J Infect Dis. 2010 Jun;14(6):e533-5.
Cicconi P, Cozzi-Lepri A, Castagna A, Trecarichi EM, Antinori A, Gatti F, Cassola G, Sighinolfi L, Castelli P, d'Arminio Monforte A; ICoNA Foundation Study Group. Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients. HIV Med. 2010 Feb;11(2):104-13.
Ghosn J, Flandre P, Cohen-Codar I, Girard PM, Chaix ML, Raffi F, Dellamonica P, Ngovan P, Norton M, Delfraissy JF; MONARK Study Group. Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial. HIV Med. 2010 Feb;11(2):137-42.
D'Agostino C, Lichtner M, Mastroianni CM, Ceccarelli G, Iannetta M, Antonucci S, Vullo V, Massetti AP. In vivo release of alpha-defensins in plasma, neutrophils and CD8 T-lymphocytes of patients with HIV infection. Curr HIV Res. 2009 Nov;7(6):650-5.
Podlekareva DN, Mocroft A, Post FA, Riekstina V, Miro JM, Furrer H, Bruyand M, Panteleev AM, Rakhmanova AG, Girardi E, Losso MH, Toibaro JJ, Caylá J, Miller RF, Obel N, Skrahina A, Chentsova N, Lundgren JD, Kirk O; HIV/TB Study Writing Group. Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina. AIDS. 2009 Nov 27;23(18):2485-95.
Camoni L, Regine V, Colucci A, Conte ID, Chiriotto M, Vullo V, Sebastiani M, Cordier L, Beretta R, Fiore JR, Tateo M, Affronti M, Cassarà G, Suligoi B. Changes in at-risk behavior for HIV infection among HIV-positive persons in Italy. AIDS Patient Care STDS. 2009 Oct;23(10):853-8.
Muratori C, Cavallin LE, Krätzel K, Tinari A, De Milito A, Fais S, D'Aloja P, Federico M, Vullo V, Fomina A, Mesri EA, Superti F, Baur AS. Massive secretion by T cells is caused by HIV Nef in infected cells and by Nef transfer to bystander cells. Cell Host Microbe. 2009 Sep 17;6(3):218-30.
d'Ettorre G, Ceccarelli G, Turriziani O, Andreotti M, Massetti P, Rizza C, Vella S, Antonelli G, Mastroianni CM, Vullo V. The absence of HIV mutations in cerebrospinal fluid and in peripheral blood mononuclear cells during a regimen containing Trizivir plus tenofovir. J Chemother. 2009 Aug;21(4):455-7.
Zazzi M, Prosperi M, Vicenti I, Di Giambenedetto S, Callegaro A, Bruzzone B, Baldanti F, Gonnelli A, Boeri E, Paolini E, Rusconi S, Giacometti A, Maggiolo F, Menzo S, De Luca A; ARCA Collaborative Group. Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting. J Antimicrob Chemother. 2009 Sep;64(3):616-24. Epub 2009 Jul 19.
Cozzi-Lepri A, Phillips AN, Martinez-Picado J, Monforte A, Katlama C, Eg Hansen AB, Horban A, Bruun J, Clotet B, Lundgren JD; EuroSIDA Study Group. Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings. J Infect Dis. 2009 Sep 1;200(5):687-97.
d'Arminio Monforte A, Cozzi-Lepri A, Castagna A, Antinori A, De Luca A, Mussini C, Caputo SL, Arlotti M, Magnani G, Pellizzer G, Maggiolo F, Puoti M; Icona Foundation Study Group. Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis. Clin Infect Dis. 2009 Aug 15;49(4):612-22.
Morsica G, Bagaglio S, Cicconi P, Capobianchi MR, Pellizzer G, Caramello P, Orani A, Moioli C, Rizzardini G, Uberti-Foppa C, Puoti M, Monforte AD; Hepa I.C.o.N.A the Icona Foundation Study Groups. Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients. J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):574-81.
Lanini S, Jarvis WR, Nicastri E, Privitera G, Gesu G, Marchetti F, Giuliani L, Piselli P, Puro V, Nisii C, Ippolito G; INF-NOS Study Group (Gruppo Italiano per lo Studio delle Infezioni Noscomiali). Healthcare-associated infection in Italy: annual point-prevalence surveys, 2002-2004. Infect Control Hosp Epidemiol. 2009 Jul;30(7):659-65. Erratum in: Infect Control Hosp Epidemiol. 2009 Oct;30(10):1029.
Kesselring AM, Wit FW, Sabin CA, Lundgren JD, Gill MJ, Gatell JM, Rauch A, Montaner JS, de Wolf F, Reiss P, Mocroft A; Nevirapine Toxicity Multicohort Collaboration. Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS. 2009 Aug 24;23(13):1689-99.
Antinori A, Ammassari A, Torti C, Marconi P, Andreoni M, Angarano G, Bonora S, Castagna A, Cauda R, Clerici M, Monforte A, De Luca A, Di Perri G, Galli M, Girardi E, Gori A, Lazzarin A, Lo Caputo S, Mazzotta F, Montella F, Mussini C, Perno CF, Puoti M, Rizzardini G, Rusconi S, Vullo V, Carosi G. Italian consensus statement on management of HIV-infected individuals with advanced disease naïve to antiretroviral therapy. Infection. 2009 Jun;37(3):270-82.
Delaugerre C, Flandre P, Chaix ML, Ghosn J, Raffi F, Dellamonica P, Jaeger H, Shürmann D, Cohen-Codar I, Van PN, Norton M, Taburet AM, Delfraissy JF, Rouzioux C; MONARK Study Group. Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy. Antimicrob Agents Chemother. 2009 Jul;53(7):2934-9. Epub 2009 May 18.
Scagnolari C, Selvaggi C, Chiavuzzo L, Carbone T, Zaffiri L, d'Ettorre G, Girardi E, Turriziani O, Vullo V, Antonelli G. Expression levels of TLRs involved in viral recognition in PBMCs from HIV-1-infected patients failing antiretroviral therapy. Intervirology. 2009;52(2):107-14.
d'Ettorre G, Ceccarelli G, Zaffiri L, Falcone M, Mastroianni CM, Venditti M, Vullo V. Infectious aortitis and spondylodiscitis in patients with endovascular stents. Minerva Med. 2009 Apr;100(2):167-70.
Musio D, Parisi E, Dionisi F, Parisi G, Caiazzo R, Bulzonetti N, Lichtner M, Raffetto N, Vullo V, Banelli E. Irradiated fields spared Stevens-Johnson syndrome in a patient undergoing radiotherapy for bone metastases. Jpn J Radiol. 2009 Feb;27(2):103-6. Epub 2009 Mar 12.
Sauzullo I, Mengoni F, Lichtner M, Massetti AP, Rossi R, Iannetta M, Marocco R, Del Borgo C, Soscia F, Vullo V, Mastroianni CM. In vivo and in vitro effects of antituberculosis treatment on mycobacterial interferon-gamma T cell response. PLoS One. 2009;4(4):e5187. Epub 2009 Apr 13.
Peters L, Mocroft A, Soriano V, Rockstroh JK, Losso M, Valerio L, Aldins P, Reiss P, Ledergerber B, Lundgren JD; EuroSIDA Study Group. Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression. J Acquir Immune Defic Syndr. 2009 Apr 15;50(5):457-63.
Antiretroviral Therapy Cohort Collaboration (ART-CC), Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d'Arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clin Infect Dis. 2009 Apr 15;48(8):1138-51.
Russo G, Pasquali P, Nenova R, Alexandrov T, Ralchev S, Vullo V, Rezza G, Kantardjiev T. Reemergence of human and animal brucellosis, bulgaria. Emerg Infect Dis. 2009 Feb;15(2):314-6.
Muratori C, Bona R, Ruggiero E, D'Ettorre G, Vullo V, Andreotti M, Federico M. DC contact with HIV-1-infected cells leads to high levels of Env-mediated virion endocytosis coupled with enhanced HIV-1 Ag presentation. Eur J Immunol. 2009 Feb;39(2):404-16.
Bonora S, Nicastri E, Calcagno A, Gonzalez de Requena D, D'Ettorre G, Sarmati L, Palmisano L, Vullo V, Di Perri G, Andreoni M. Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation. J Med Virol. 2009 Mar;81(3):400-5.
Sarmati L, Andreoni C, Nicastri E, Tommasi C, Buonomini A, D'Ettorre G, Corpolongo A, Dori L, Montano M, Volpi A, Narciso P, Vullo V, Andreoni M. Prognostic factors of long-term CD4+count-guided interruption of antiretroviral treatment. J Med Virol. 2009 Mar;81(3):481-7.
Russo G, Lichtner M, Traditi F, Vullo V. Is the time for an AIDS-free new generation different in resource-limited and industrialized countries? AIDS. 2009 Jan 28;23(3):293-6.
Orsi GB, d'Ettorre G, Panero A, Chiarini F, Vullo V, Venditti M. Hospital-acquired infection surveillance in a neonatal intensive care unit. Am J Infect Control. 2009 Apr;37(3):201-3.

Roma 25/02/2015 Firma

Autorizzo il trattamento dei dati personali
Roma, 25/02/2015